Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Burroughs_Wellcome
|
| gptkbp:activities |
inhibits reverse transcriptase
|
| gptkbp:appointed_by |
oral tablet
|
| gptkbp:approves |
gptkb:2001
gptkb:FDA |
| gptkbp:brand |
gptkb:Viread
|
| gptkbp:can_be_used_with |
gptkb:lamivudine
gptkb:emtricitabine |
| gptkbp:class |
nucleotide reverse transcriptase inhibitor
|
| gptkbp:contraindication |
renal impairment
|
| gptkbp:developed_by |
gptkb:Gilead_Sciences
|
| https://www.w3.org/2000/01/rdf-schema#label |
Tenofovir
|
| gptkbp:ingredients |
C23 H31 N5 O8 P
|
| gptkbp:is_available_on |
generic drug
|
| gptkbp:is_used_for |
HIV treatment
Hepatitis B treatment |
| gptkbp:manager |
oral
|
| gptkbp:pharmacokinetics |
bioavailability 25%
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea |